We are clinical-stage therapeutics company focused on developing potential first-in-class clinical and preclinical small molecule pan-caspase and caspase selective inhibitors that protect the body’s natural process to restore immune function. Our product candidates include emricasan, CTS-2090 and CTS-2096. Currently, we are developing emricasan for acute bacterial skin and skin structure infections (ABSSSI) as well evaluating its use for other infectious diseases. Our pipeline also includes novel preclinical product candidates including CTS-2090 and CTS-2096, which are highly selective small molecule inhibitors of caspase-1 designed for the treatment of certain inflammatory diseases.
Previously, our focus was on developing our proprietary hypoxia-generated growth factor technology platform and stem cell-free biologic products Human Multipotent Cell Conditioned Media, or CCM and our Human Extracellular Matrix, or hECM, as potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function. We are actively seeking collaboration partners or acquirers for our CCM and hECM.